( May 8, 2026, 4:06 PM EDT) -- WASHINGTON, D.C. — The manufacturers of mifepristone, one of two drugs used to induce early termination of pregnancy, are not entitled to a stay or vacatur of a decision by the Fifth Circuit U.S. Court of Appeals that granted Louisiana’s motion to stay the U.S. Food and Drug Administration’s 2023 decision that removed the in-person dispensing requirement for the drug because there is not a reasonable probability that the court will grant certiorari, Louisiana tells the U.S. Supreme Court in a May 8 response to the applications for a stay....